| 龙婷婷.奈达铂联合紫杉醇同步放疗治疗中晚期宫颈癌的疗效及不良反应观察[J].安徽医药,2016,20(5):965-968. |
| 奈达铂联合紫杉醇同步放疗治疗中晚期宫颈癌的疗效及不良反应观察 |
| Efficacy and adverse reactions of nedaplatin combined with paclitaxel plus intensity-modulated radiotherapy on advanced cervix cancerLONG Ting-ting (Anqing Hospital Affiliated to Anhui Medical University,Anqing,Anhui 246000,China)Abstract: |
| 投稿时间：2015-11-17 |
| DOI： |
| 中文关键词: 宫颈肿瘤 紫杉酚 顺铂 化放疗 |
| 英文关键词: Uterine Cervical Neoplasms Paclitaxel Cisplatin Chemoradiotherapy |
| 基金项目: |
|
| 摘要点击次数: 3233 |
| 全文下载次数: 98 |
| 中文摘要: |
| 目的 观察紫杉醇结合奈达铂同时予以调强放疗治疗中晚期宫颈癌的治疗效果和不良反应。方法 选择ⅡB～ⅣA期宫颈癌60例,分为 A、 B组,每组30例,两组均予以调强放疗,放疗分次量每次2 Gy,每周5次,总剂量50 Gy,体外照射开始后第2周,采用192Ir高剂量率子宫腔内后装照射腔内照射每周1次,A点剂量每次5 Gy,共6次。放疗期间 A组采用紫杉醇联合奈达铂方案化疗, B组采用紫杉醇联合顺铂方案,两组均每周1次,共4~6周期。观察近、远期治疗效果和副反应。结果 A组近期有效率93.3%,B组为90.0%,差异无统计学意义(P=0.500)；A组1、2、3年生存率为90.0%、72.8%、56.6%, B组1、2、3年生存率为83.3%、65.3%、49.0%,两组总生存率差异无统计学意义(P=0.413)；A组中位无进展生存时间为28个月,B组为22个月,差异无统计学意义(P=0.352)。A组发生Ⅰ~Ⅳ度骨髓抑制者为26例,B组为21例,差异无统计学意义(P=0.117)；A组发生Ⅰ~Ⅳ度胃肠道反应者为21例,B组为28例,差异有统计学意义(P=0.020)。结论 紫杉醇联合奈达铂同步调强放疗治疗中晚期宫颈癌患者可获得较高生存率,并且在不良反应方面较轻,患者依从性好。 |
| 英文摘要: |
| Objective To observe the efficacy and toxicity of nedaplatin combined with paclitaxel plus radiotherapy in treatment of advanced cervix cancer.Methods Sixty cases of cervical cancer in IIB to IVA stage were randomized into group Aand group B,with 30 cases in each group.The external irradiation dose of radiotherapy was2 Gy per time,5 d/w, with a total dose of 50 Gy;192 Ir high-dose-rate after loading unit was adopted for branchytherapy one week after external radiotherapy,at a dose of 5 Gy per time in Apoint for 6 times.During radiotherapy group Aadopted paclitaxel combined with nedaplatin chemotherapy,while group Badopted paclitaxel combined with cisplatin.Treatment in both groups were once a week with a total of 4 ~ 6 cycles.The clinical effects and adverse reactions were compared.Results The short-term effective rates of group Aand group Bwere 93.3% and 90%,respectively.The difference was not statistically significant (P=0.500).One-,two-,three-year survival rates were 90.0%,72.8%,56.6% in group Aand 83.3%,65.3%,49.0% in group B.There was no statistically significant difference (P=0.413).Median progression-free survival time was 28 months in group Aand 22 months in group Bwith no statistically significant difference (P=0.352).The major adverse reactions were bone marrow suppression, gastrointestinal tract reaction.I - IV degree bone marrow suppression occurred in 26 cases of group Aand 21 cases of group Bwith no statistically significant difference (P=0.117).I - IV degree gastrointestinal reaction occurred in 21 cases of group Aand 28 cases of group Bwith statistically significant difference (P=0.020).Conclusions Nedaplatin combined with paclitaxel plus intensity-modulated radiation therapy in patients with locally advanced cervical cancer can obtain higher survival rate,lighter adverse reactions and good patient compliance. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
